BofA lowered the firm’s price target on Omnicell (OMCL) to $32 from $34 and keeps a Neutral rating on the shares. BofA appreciates Omnicell’s leading position in a duopolistic pharmacy automation market, but limited visibility into components of product revenue growth creates uncertainty near-term, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMCL:
- Omnicell’s Growth Uncertainty Amidst Market Challenges: A Hold Rating Analysis
- Positive Growth Outlook for Omnicell’s Automation Technology Justifies Buy Rating
- Omnicell CFO Nchacha Etta to Step Down
- Omnicell management to meet with Piper Sandler
- Down Over 30%: Wells Fargo Says Now Is the Time to Load Up on These 2 Beaten-Down Stocks